Vestal Point Capital LP Has $22.03 Million Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Vestal Point Capital LP reduced its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 33.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 485,000 shares of the company’s stock after selling 240,000 shares during the quarter. Janux Therapeutics makes up approximately 1.7% of Vestal Point Capital LP’s holdings, making the stock its 20th largest holding. Vestal Point Capital LP owned about 0.92% of Janux Therapeutics worth $22,034,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Summit Securities Group LLC bought a new stake in shares of Janux Therapeutics during the second quarter worth $29,000. Amalgamated Bank raised its stake in shares of Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after acquiring an additional 368 shares during the last quarter. Plato Investment Management Ltd acquired a new position in shares of Janux Therapeutics during the second quarter worth approximately $42,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Janux Therapeutics in the second quarter valued at approximately $151,000. 75.39% of the stock is currently owned by institutional investors.

Insider Activity

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the completion of the transaction, the insider now directly owns 67,592 shares in the company, valued at $3,106,528.32. This trade represents a 42.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $51.60, for a total value of $1,290,000.00. Following the transaction, the chief executive officer now directly owns 257,054 shares in the company, valued at $13,263,986.40. This trade represents a 8.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 445,610 shares of company stock worth $20,578,666 over the last three months. Corporate insiders own 29.40% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on JANX. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research report on Thursday, November 7th. Leerink Partners began coverage on Janux Therapeutics in a research report on Friday, November 22nd. They issued an “outperform” rating and a $79.00 price objective for the company. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a research report on Thursday, November 7th. Finally, UBS Group began coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Janux Therapeutics has an average rating of “Buy” and a consensus price target of $67.70.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $46.39 on Friday. Janux Therapeutics, Inc. has a twelve month low of $7.79 and a twelve month high of $65.60. The company’s fifty day moving average is $49.98 and its 200-day moving average is $45.83.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business’s quarterly revenue was down 82.6% on a year-over-year basis. Analysts expect that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.